Safety and efficacy of cilostazol in the management of intermittent claudication

Vascular Health and Risk Management

Volumn 4, Issue 6, 2008, Pages 1197-1203

  Chi, Yung Wei ^a   Lavie, Carl J ^a   Milani, Richard V ^a   White, Christopher J ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Cilostazol; Intermittent claudication; Peripheral arterial disease; Supervised exercise therapy

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CILOSTAZOL; CLOPIDOGREL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PENTOXIFYLLINE; PLACEBO;

ARTERY DISEASE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELUTING STENT; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; DYSPNEA; EXERCISE; FECES; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART PALPITATION; HUMAN; HYPERTENSION; INTERMITTENT CLAUDICATION; KINESIOTHERAPY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PERIPHERAL EDEMA; QUALITY OF LIFE; RESTENOSIS; REVIEW; SIDE EFFECT; THROMBOCYTE ACTIVATION; TREADMILL EXERCISE; VASCULAR PATENCY;

CARDIOVASCULAR AGENTS; EXERCISE TOLERANCE; HUMANS; INTERMITTENT CLAUDICATION; PERIPHERAL VASCULAR DISEASES; QUALITY OF LIFE; TETRAZOLES; TREATMENT OUTCOME;

EID: 60249088588     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Agrawal NK, Maiti R, Dash D, et al. 2007. Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients. Pharmacol Res, 56:118-23.
2. Ahn Y, Jeong MH, Jeong JW, et al. 2008. Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients - clilostazol for diabetic patients in drug-eluting stent (CIDES) trial. Circ J, 72:35-9.
3. Ainsworth BE, Haskell WL, Whitt MC, et al. 2000. Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc, 32(Suppl):S498-504.
4. Aoki M, Morishita R, Hayashi S, et al. 2001. Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model. Diabetologia, 44:1034-42.
5. Beebe, HG, Dawson DL, Cutler BS, et al. 1999. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med, 159:2041-50.
6. Bramer SL, Forbes WP, Mallikaarjun S. 1999. Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease. Clin Pharmacokinet, 37(Suppl 2):1-11.
7. Bramer SL, Tata PNV, Mallikaarjun S. 1997. Disposition of 14 C-cilostazol after single dose administration to healthy human subjects. Phar Res, 14(11 Suppl):S612.
8. Chapman, TM, Goa KL. 2003. Cilostazol: a review of its use in intermittent claudication. Am J Cardiovasc Drugs, 3:117-38.
9. Cleanthis M, Bhattacharya V, Smout J, et al. 2005. Combined aspirin and cilostazol treatment is associated with reduced platelet aggregation and prevention of exercise induced platelet activation. Yearb Soc Acad Res Surg, 39.
10. Dawson DL, Cutler BS, Meissner MH, et al. 1998. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation, 98:678-86.
11. Dawson, DL, Cutler BS, Hiatt WR, et al. 2000. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med, 109:523-30.
12. Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, et al. 2005. Cilostazol for Restenosis Trial (CREST) Investigators. Coronary stent restenosis in patients treated with cilostazol. Circulation, 112:2826-32.
13. Elam MB, Heckman J, Crouse JR, et al. 1998. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol, 18:1942-7.
14. Gardner AW, Poehlman ET. 1995. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA, 274:975-80.
15. Hashimoto A, Miyakoda G, Hirose Y, et al. 2006. Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism. Atherosclerosis, 189:350-7.
16. Hayashi S, Morishita R, Matsushita H, et al. 2000. Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21. Hypertension, 35:237-43.
17. Hiatt WR, Wolfel EE, Regensteiner JG. 1992. Skeletal muscle carnitine metabolism in patients with unilateral peripheral arterial disease. J Appl Physiol, 73:346-53.
18. Hiatt WR. 2001. Medical treatment of peripheral arterial disease and claudication. N Engl J Med, 344:1608-21.
19. Hiatt WR. 2002. Pharmacologic therapy for peripheral arterial disease and claudication. J Vasc Surg, 36:1283-91.
20. Hiatt WR. 2006. The US experience with cilostazol in treating intermittent claudication. Atheroscler Suppl, 6:21-31.
21. Hiatt, WR, Nawaz D, Brass EP. 1987. Carnitine metabolism during exercise in patients with peripheral vascular disease. J Appl Physiol, 62:2383-7.
22. Ikeda Y, Kikuchi M, Murakami H, et al. 1987. Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo. Randomized, double-blind cross-over study. Arzneimittelforschung, 37:563-6.
23. Ishii H, Kumada Y, Toriyama T, et al. 2008. Cilostazol improves long-term patency after percutaneous transluminal angioplasty in hemodialysis patients with peripheral artery disease. Clin J Am Soc Nephrol, 3:1034-40.
24. Kumar M, Bhattacharya V. 2007. Cilostazol: a new drug in the treatment intermittent claudication. Recent Patents Cardiovasc Drug Discov, 2:181-5.
25. Lee TM, Su SF, Hwang JJ, et al. 2001. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. Atherosclerosis, 158:471-6.
26. Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication. 2000. Cochrane Database Syst Rev, 2:CD000990.
27. Manickavasagam S, Ye Y, Lin Y, et al. 2007. The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation. Cardiovasc Drugs Ther, 21:321-30.
28. Milani RV, Lavie CJ. 2007. The role of exercise training in peripheral arterial disease. Vasc Med, 12:351-8.
29. Money SR, Herd JA, Isaacsohn JL, et al. 1998. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg, 27:267-74; discussion 274-5.
30. Packer M, Carver JR, Rodeheffer RJ, et al. 1991. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med, 325:1468-75.
31. Pratt CM. 2001. Analysis of the cilostazol safety database. Am J Cardiol, 87:28D-33D.
32. Regensteiner JG, Ware JE Jr, McCarthy WJ, et al. 2002. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc, 50:1939-46.
33. Strandness DE, Dalman R, Panian S, et al. 1998. Two doses of cilostazol versus placebo in the treatment of claudication: results of a randomized, multicenter trial. Circulation, 98(17 Suppl 1):1-12.
34. Takahashi S, Oida K, Fujiwara R, et al. 1992. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol, 20:900-6.
35. Tamai Y, Takami H, Nakahata R, et al. 1999. Comparison of the effects of acetylsalicylic acid, ticlopidine and cilostazol on primary hemostasis using a quantitative bleeding time test apparatus. Haemostasis, 29:269-76.
36. Tani T, Sakurai K, Kimura Y, et al. 1992. Pharmacological manipulation of tissue cyclic AMP by inhibitors. Effects of phosphodiesterase inhibitors on the functions of platelets and vascular endothelial cells. Adv Second Messenger Phosphoprotein Res, 25:215-27.